Efficacy and toxicity of docetaxel combination chemotherapy for advanced squamous cell cancer of the head and neck
Efficacy and toxicity of docetaxel combination chemotherapy for advanced squamous cell cancer of the head and neck
复制标题
DOI：
10.3892/mco.2017.1281
复制
发表时间：
2017-07-01
影响因子：
1.2
通讯作者：
Pecher, Gabriele
中科院分区：
文献类型：
--
作者：
Albers, Andreas E.;Grabow, Regina;Pecher, Gabriele
本研究的目的是通过对2007年至2012年期间在一家机构接受治疗的患者进行回顾性队列研究，评价多西他赛联合5-氟尿嘧啶和顺铂治疗可治愈或转移性/复发性头颈癌患者的临床有效性和毒性。接受包括多西他赛在内的联合治疗的局部晚期、转移性和/或复发性头颈部鳞状细胞癌（SCCHN）患者被视为合格。从患者图表中检索生存数据、临床副作用、生活质量（QoL）和毒性特征，根据美国国家癌症研究所常见毒性标准（第4版）和实体瘤疗效评价标准（第1.1版）进行分析和评分。总有效率为86%，3年生存率为65.1%。中位无进展生存期为32个月。3年后局部复发率为16.9%，远处转移率为10.4%。白细胞减少症（58%）和贫血（51%）是最常见的血液学毒性，其次是肝毒性（53%）和恶心（27%）。治疗完成后，共有31%的患者的QoL受损。总之，多西他赛联合顺铂和5-氟尿嘧啶可有效延长局部晚期和/或复发性转移性SCCHN患者的生存期。总生存期、无进展生存期和缓解率与既往临床试验报告一致。因此，该治疗方案推荐用于治疗性和姑息性SCCHN患者。
The aim of the present study was to evaluate the clinical effectiveness and toxicity of docetaxel with 5-fluorouracil and cisplatin as combination treatment in patients with curable or metastatic/recurrent head and neck cancer by a retrospective cohort study of patients treated at a single institution between 2007 and 2012. Patients with locally advanced, metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN), who were treated with a combination therapy including docetaxel, were considered as eligible. Survival data, clinical side effects, quality of life (QoL) and toxicity profile were retrieved from patient charts, analyzed and scored according to the National Cancer Institute Common Toxicity Criteria, version 4, and the Response Evaluation Criteria In Solid Tumors, version 1.1. An overall response rate of 86% and a 3-year survival of 65.1% were observed. The median progression-free survival was 32 months. The cumulative incidence after 3 years was 16.9% for local recurrence and 10.4% for distant metastasis. Leukopenia (58%) and anemia (51%) were the most common hematological toxicities, followed by hepatotoxicity (53%) and nausea (27%). A total of 31% of the patients experienced a compromise in their QoL following therapy completion. In conclusion, docetaxel in combination with cisplatin and 5-fluorouracil was found to effectively prolong survival in patients with locally advanced and/or recurrent metastatic SCCHN. The overall survival, progression-free survival and response rates were in accordance with those reported by previous clinical trials. Therefore, this therapy protocol is recommended for patients with SCCHN in the curative as well as the palliative settings.